After the monoclonal antibody nirsevimab (Beyfortus) became available to prevent respiratory syncytial virus (RSV) in infants ...

In a recent study of a population of infants, published online May 6 in Pediatrics, 72 percent of infants were found to be ...

Overall, 72% of 36,949 infants were immunized in the 2023-2024 RSV season with either the bivalent RSV prefusion F protein ...

A monoclonal antibody -- a protein created in a lab which mimics the work of a natural antibody -- could be highly effective ...

A gene expression map in monkeys has shown that drug effectiveness, alcohol tolerance and carbohydrate metabolism all vary ...

Monoclonal antibody nirsevimab provides strong real-world protection against severe RSV in infants, suggests meta-analysis ...

The U.S. Centers for Disease Control and Prevention (CDC) recommends that all babies be protected from RSV by one of two ...

The seasonal timing of when infants receive the new respiratory syncytial virus (RSV) immunization is crucial for ensuring ...

"Nirsevimab is highly effective in preventing RSV-related outcomes in infants, with a pooled real-world effectiveness of 83 ...

Findings of the study, published in The Lancet Child and Adolescent Health journal, show that injecting infants with the antibody 'nirsevimab' reduces risk of RSV-related hospitalisations by 83 ...

Under the agreement, Dr Reddy's will have exclusive rights from SHIPL to promote and distribute Beyfortus within the country ...